Visionbridge Life Sciences Management, L.P. – Trademark Portfolio
Entity Type: 13
Visionbridge Life Sciences Management, L.P. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 37 (Building & Construction) — 3 filings in this category. The portfolio also extends into Class 36 (Insurance & Financial) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include V, VISIONBRIDGE, and V VISIONBRIDGE. The owner is based in New York, NY.
9 West 57th Street, 48th Floor
New York, NY 10019
Showing of trademarks Trademarks
Trademark Classifications
Visionbridge Life Sciences Management, L.P.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Insurance; financial affairs; monetary affairs; real estate affairs
Frequently Asked Questions
How many trademarks does Visionbridge Life Sciences Management, L.P. have?
Visionbridge Life Sciences Management, L.P. has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.
What trademark classes does Visionbridge Life Sciences Management, L.P. file in?
Visionbridge Life Sciences Management, L.P. files trademarks across 2 Nice Classification classes. The most active classes are Class 37 (Building & Construction), Class 36 (Insurance & Financial). Class 37 covers building construction; repair; installation services.
What are Visionbridge Life Sciences Management, L.P.'s most well-known trademarks?
Visionbridge Life Sciences Management, L.P.'s registered trademark portfolio includes well-known marks such as V, VISIONBRIDGE, and V VISIONBRIDGE. These are among 3 currently registered trademarks in the portfolio.
What is Visionbridge Life Sciences Management, L.P.'s trademark registration success rate?
Visionbridge Life Sciences Management, L.P. has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.